Characteristics of patients admitted to hospital with chronic obstructive pulmonary disease

New Zealand Medical Journal

Volumn 110, Issue 1048, 1997, Pages 272-275

  Poole, Phillippa J ^a   Bagg, Brigitte ^a   Brodie, Susanne M ^a   Black, Peter N ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DAILY LIFE ACTIVITY; FEMALE; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; PATIENT ATTITUDE; PROSPECTIVE STUDY; SMOKING; SOCIOECONOMICS;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; FEMALE; HOSPITALIZATION; HUMANS; LUNG DISEASES, OBSTRUCTIVE; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PROSPECTIVE STUDIES; SMOKING; SOCIOECONOMIC FACTORS;

EID: 0031586158     PISSN: 00288446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331: 778-84.
2. Satterthwaite P. A randomised intervention study to examine the effect on immunisation coverage of making influenza vaccine available at no cost. NZ Med J 1997; 110: 58-60.
3. Morgan MD, Quirk FH, Singh S. Rehabilitation for people with chronic lung disease. Quality Health Care 1995; 4: 284-8.
4. Strijbos JH, Postma DS, van Altena R, Gimeno F, Koeter GH. A comparison between an outpatient hospital-based pulmonary rehabilitation program and a home-care pulmonary rehabilitation program in patients with COPD-a follow-up of 18 months. Chest 1996; 109: 366-72.
5. 1. JAMA 1994; 272: 1497-505.
6. O'Hagan J. Prevention of chronic obstructive pulmonary disease: a challenge for the health professions. NZ Med J 1996; 109: 1-3.
7. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): conceptual framework and item selection. Med Care 1992; 30: 473-83.
8. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77-S120.
9. Report working party. Standardized lung function testing. Bull Eur Physiopathol Respir 1983; 19 (Suppl. 5): 1-95.
10. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
11. Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996; 154: 407-12.
12. Town GI, Watson P, Holbrook N, Dwan C, Drennan C. A self-management plan for patients with COPD. Eur Respir J 1996; 9 (Suppl 23): P2636.
13. Yellowlees PM, Alpers JH, Bowden JJ, Bryant GD, Ruffin RE. Psychiatric morbidity in patients with chronic airflow obstruction. Med J Aust 1987; 146: 305-7.
14. Everts RJ, Hanger HC, Jennings LC, Hawkins A, Sainsbury R. Outbreaks of influenza A among elderly hospital inpatients. NZ Med J 1996; 109: 272-4.
15. Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease-a meta-analysis. Ann Intern Med 1991; 114: 216-23.
16. Jenkins C, Mitchell C, Irving L, Frith P, Young I. Guidelines for the management of chronic obstructive pulmonary disease. Modern Med 1995; 38: 132-46.
17. Murciano D, Auclair M-H, Pariente R, Aubier M. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med 1989; 320: 1521-5.
18. Mahler DA, Matthay RA, Snyder PE, Wells CK, Loke J. Sustained-reiease theophylline reduces dyspnea in nonreversible obstructive airways disease. Am Rev Respir Dis 1985; 131: 22-5.
19. Siafakis NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8: 1398-420.
20. Karpel JP. Bronchodilator responses to anticholinergic and beta-adrenergic agents in acute and stable COPD. Chest 1991; 99: 871-6.
21. 2-adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide), given by aerosol alone or in sequence. N Engl J Med 1986; 315: 735-9.
22. Blosser SA, Maxwell SL, Reeves-Hoche MK, Localio AR, Zwillich CW. Is an anticholinergic agent superior to a beta 2-agonist in improving dyspnea and exercise limitation in COPD? Chest 1995; 108: 730-5.
23. Jenkins SC, Heaton RW, Fulton TJ, Moxham J. Comparison of domiciliary nebulised salbutamol and salbutamol from a metered-dose inhaler in stable chronic airflow limitation. Chest 1987; 91: 804-7.
24. Poole PJ, Brodie SM, Black PN. A comparison of the effects of nebulised saline and terbutaline on breathlessness in patients with COPD. Aust NZ J Med 1997; 27: A242.
25. Lacasse Y, Wong E, Guyatt GH, King D, Cook DJ, Goldstein RS. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet 1996; 348: 1115-9.